Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 b single dose expansion clinical trial to evaluate Rhenium-(186Re)-obisbemeda

Next Previous
Trial Profile

Phase 1 b single dose expansion clinical trial to evaluate Rhenium-(186Re)-obisbemeda

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rhenium (186Re) obisbemeda (Primary)
  • Indications Brain cancer; Glioma; Meningeal carcinomatosis; Peritoneal cancer; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 18 Feb 2025 According to the Plus Therapeutics Media Release, company announced that it has closed a private placement with aggregate initial upfront proceeds of approximately $3.7 million and received a $2.0 million advance payment from CPRIT as part of its existing $17.6 million grant award. This capital, along with expected grant allocations later in 2025, is expected to fully support the completion of two planned LM trials, strategically positioning the company for a pivotal trial in 2026.
  • 28 Nov 2024 New trial record
  • 25 Nov 2024 According to a Plus Therapeutics media release, Planning is underway for a Phase 1b single dose expansion cohort trial using the Cohort 4 dose of 44 mCi, which is expected to fully enroll in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top